Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Griffith on the brink of technological breakthrough in vaccine development

Griffith University researchers are on the brink of a technological breakthrough in vaccine development with a possible new vaccine modality.

23 Aug 2023

Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery

In this interview, News-Medical had the opportunity to speak with Dr. Xiaobing Han, Principal Scientist for Antibody Discovery at Rapid Novor.

From Rapid Novor Inc 23 Aug 2023

Texas Heart Institute receives $1.14 million grant to develop first-in-class drug to treat cardiovascular disease

The National Heart, Lung, and Blood Institute (NHLBI) recently awarded The Texas Heart Institute (THI) a two-year, $1.14 million grant to develop a novel, first-in-class drug to treat cardiovascular disease (CVD) as a significant improvement to current treatment regimens -; specifically for adverse events arising from atherosclerosis.

22 Aug 2023

Genetically diverse mouse models offer new insights into Alzheimer's disease

A new study by Indiana University School of Medicine researchers uses more genetically diverse mouse models to study the accumulation and spread of abnormal tau protein deposits in the brain-;a known sign of Alzheimer's disease and several other neurodegenerative diseases.

22 Aug 2023

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck

Illumina Inc., a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of VUMC, today announced the five founding members of the Alliance for Genomic Discovery.

17 Aug 2023

Study sheds light on how cold temperatures affect appetite

Neuroscientists at Scripps Research have identified brain circuits that make mammals want to eat more when they are exposed to cold temperatures.

16 Aug 2023

Illustrating the safety of a new drug treatment designed for spinal cord injury

New orally available drug for spinal cord injury found to be safe and tolerable in healthy participants.

11 Aug 2023

Study explores the use of existing medicines to revolutionize cancer treatment

In a recent study published in the journal of Genes & Diseases, Research team led by Lu explores the potential for the use of FDA-approved hypertension and EMA-approved cough medicines to revolutionize cancer treatment.

10 Aug 2023

Machine learning can accurately predict subtypes of Parkinson's disease

Researchers at the Francis Crick Institute and UCL Queen Square Institute of Neurology, working with technology company Faculty AI, have shown that machine learning can accurately predict subtypes of Parkinson's disease using images of patient-derived stem cells.

10 Aug 2023

Experimental drug can reduce symptoms of inflammatory bowel disease in pre-clinical models

A new study of mice and lab-grown human colon "organoids" indicates that an experimental drug developed by Johns Hopkins Medicine researchers can substantially reduce symptoms of inflammatory bowel disease (IBD) in pre-clinical models.

10 Aug 2023

How conversion between different types of cell death contributes to disease

Researchers elucidate the role of cell death in the pathogenesis of different diseases.

10 Aug 2023

Research uncovers potential route to treating vascular dementia

Groundbreaking new research has uncovered a potential route to developing the first ever drug treatments for vascular dementia, that directly target a cause of the condition.

7 Aug 2023

New antibody shows promise in reversing carfentanil overdoses

An antibody in single-chain fragment variable (scFv) format that binds to the powerful opioid carfentanil was shown to reverse signs of carfentanil overdose in preclinical tests conducted by scientists at Scripps Research.

7 Aug 2023

Miniature heart model holds the key to saving lives and enhancing patient outcomes

Discovery led by Prof. Yaakov Nahmias from the Hebrew University marks a new era in cardiovascular research, multi-chambered, self-paced miniature heart model, holding the key to saving lives and enhancing patient outcomes.

7 Aug 2023

Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Screening Service

Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, today announced it has received notification from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) that the Company is now a member of the UK GLP (Good Laboratory Practice) Compliance Monitoring Programme, and is, therefore, able to offer GLP compliant hERG ion channel screening services to the global life sciences community.

From Metrion Biosciences Limited 7 Aug 2023

Penn State researchers develop new method for creating cyclopropanes

Chemical structures called cyclopropanes can increase the potency and fine-tune the properties of many drugs, but traditional methods to create this structure only work with certain molecules and require highly reactive-;potentially explosive-;ingredients. Now, a team of researchers from Penn State has identified and demonstrated a safe, efficient and practical way to create cyclopropanes on a wide variety of molecules using a previously undescribed chemical process.

4 Aug 2023

Insilico Medicine's new AI tool shows promise in predicting clinical trial outcomes

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has demonstrated that it can predict the outcome of Phase II to Phase III clinical trial success using its proprietary transformer-based AI clinical trial prediction tool called inClinico with a high degree of accuracy.

3 Aug 2023

Pharmatech: The Art of AI-Driven Drug Design with Exscientia

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Garry Pairaudeau, Chief Technology Officer at Exscientia, about pharmatech, AI, and more.

From Society for Laboratory Automation and Screening (SLAS) 3 Aug 2023

Insilico Medicine uses AI to discover novel SIK2 inhibitors

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the application of multiple generative AI models and AlphaFold structures for drug discovery.

2 Aug 2023

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research.

1 Aug 2023